Citations

Mayo Clinic

Clear

9374 citation(s) found for "Ly, Thomas".

Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy
Visco, Carlo , Kliche, Kay Oliver, Nadali, Gianpaolo , Viviani, Simonetta , Bonfante, V., Notti, Paola, Rassidakis, George Z., Peethambaram, Prema P. , Wilder, Richard B. , Gianni, Massimo, Bonadonna, Gianni, Pizzolo, Giovanni, Pangalis, Gerassimos A. , Cabanillas, Fernando , Sarris, Andreas H., Vassilakopoulos, Theodoros P. , Medeiros, L. Jeffrey , Witzig, Thomas E.

Leukemia & Lymphoma | August 10, 2004 | Volume: 45 | Issue: 10 | Pages: 2085-2092

10.1080/10428190410001712234 | PMID 15370254 Get It

Evaluation of the TRUGENE HCV 5′NC Genotyping Kit with the New GeneLibrarian Module 3.1.2 for Genotyping of Hepatitis C Virus from Clinical Specimens
Germer, Jeffrey J., Rosser, Michael, Thompson, Amber , Mitchell, P. Shawn, Smith, Thomas F., Elagin, Slava, Yao, Joseph D. , Majewski, David

Journal of Clinical Microbiology | August 5, 2004 | Volume: 42 | Issue: 8 | Pages: 3911-3911

10.1128/jcm.42.8.3911.2004 Get It

Hemangioblastoma of the Optic Nerve
Kerr, Daniel J., Scheithauer, Bernd W., Miller, Gary M. , Ebersold, Michael J., McPhee, Thomas J.

Neurosurgery | July 30, 2004 | Volume: 36 | Issue: 3 | Pages: 573-581

10.1097/00006123-199503000-00017 Get It

Primary Epithelioid Sarcoma of the Dura: Case Report
Kurtkaya-Yapıcıer, Özlem, Scheithauer, Bernd W., Dedrick, David J., Wascher, Thomas M.

Neurosurgery | July 29, 2004 | Volume: 50 | Issue: 1 | Pages: 198-203

10.1097/00006123-200201000-00030 | PMID 11852861 Get It

Hemofiltration but Not Steroids Results in Earlier Tracheal Extubation following Cardiopulmonary Bypass
Oliver, William C., Nuttall, Gregory A. , Orszulak, Thomas A., Bamlet, William R. , Ereth, Mark H. , Schaff, Hartzell V. , Bamlet, William R , Schaff, Hartzell

Anesthesiology | July 23, 2004 | Volume: 101 | Issue: 2 | Pages: 327-339

10.1097/00000542-200408000-00013 | PMID 15277915 Get It

Background Activation of the inflammatory cascade is thought to account for some of the respiratory dysfunction and prolonged mechanical ventilation associated with cardiopulmonary bypass. The objective of this investigation was to identify whether perioperative steroids or hemofiltration during cardiopulmonary bypass, by their attenuation of inflammation, would reduce duration of mechanical ventilation after cardiac surgery. Methods After Institutional Review Board approval and informed consent, 192 patients scheduled to undergo elective primary coronary artery bypass grafting or valvular replacement or repair were randomized in a double-blind prospective study into three groups. One group (Control) received saline at induction and at 6-h intervals for four doses. Another group (Hemofil) received saline and hemofiltration to obtain 27 ml/kg of hemofiltrate. The final group (Steroid) received 1 g methylprednisolone before anesthesia induction and then 4 mg of dexamethasone at 6-h intervals for four doses. All patients underwent normothermic cardiopulmonary bypass and received propofol for postoperative sedation. Separate two-sample comparisons were performed to compare each experimental group versus the control group using the Wilcoxon rank sum test for continuous variables and Fisher exact test for categorical variables. In all cases, two-tailed P values </= 0.05 were considered statistically significant. Results The median time until the patient reached an intermittent mandatory ventilation of 4/min (258.5 versus 385.0 min, respectively; P = 0.02) and tracheal extubation (352.0 versus 518.0 min; P = 0.03) was significantly reduced for group Hemofil but no different for Steroid compared to Control. Conclusions Hemofiltration and steroids are both previously reported to attenuate the inflammatory response but only hemofiltration reduced time to tracheal extubation for adults after cardiopulmonary bypass in this study.
Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , King, Talmadge E. , Raghu, Ganesh , Lynch, Joseph P., Colby, Thomas V. , Gross, Barry H., Kazerooni, Ella A. , Toews, Galen B., Long, Qi , Murray, Susan , Lama, Vibha N. , Gay, Steven E., Long, Qi , Travis, William D. , Martínez, Fernando J. , Long, Qi

American Journal of Respiratory and Critical Care Medicine | July 15, 2004 | Volume: 170 | Issue: 8 | Pages: 904-910

10.1164/rccm.200402-147oc | PMID 15256390 Get It

Abstract Current guidelines recommend that the clinician, radiologist, and pathologist work together to establish a diagnosis of idiopathic interstitial pneumonia. Three clinicians, two radiologists, and two pathologists reviewed 58 consecutive cases of suspected idiopathic interstitial pneumonia. Each participant was provided information in a sequential manner and was asked to record their diagnostic impression and level of confidence at each step. Interobserver agreement improved from the beginning to the end of the review. After the presentation of histopathologic information, radiologists changed their diagnostic impression more often than did clinicians. In general, as more information was provided the confidence level for a given diagnosis improved, and the diagnoses rendered with a high level of confidence were more likely congruent with the final pathologic consensus diagnosis. The final consensus pathologist diagnosis was idiopathic pulmonary fibrosis in 30 cases. Clinicians identified 75% and radiologists identified 48% of these cases before presentation of the histopathologic information. Histopathologic information has the greatest impact on the final diagnosis, especially when the initial clinical/radiographic diagnosis is not idiopathic pulmonary fibrosis. We conclude that dynamic interactions between clinicians, radiologists, and pathologists improve interobserver agreement and diagnostic confidence.
Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Benson, Al B. , Catalano, Robert B., Engelking, Constance, Martenson, James A., McCallum, Richard W. , Mitchell, Edith P. , O’Dorisio, Thomas M. , Wadler, Scott, Ajani, Jaffer A. , Kornblau, Steven M. , Vokes, Everett E.

Journal of Clinical Oncology | July 14, 2004 | Volume: 22 | Issue: 14 | Pages: 2918-2926

10.1200/jco.2004.04.132 | PMID 15254061 Get It

Purpose To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea. Methods An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines previously published by this group in the Journal of Clinical Oncology in 1998. MEDLINE searches were performed and the relevant literature published since 1998 was reviewed by all panel members. The treatment recommendations and algorithm were revised by panel consensus. Results A recent review of early toxic deaths occurring in two National Cancer Institute-sponsored cooperative group trials of irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer has led to the recognition of a life-threatening gastrointestinal syndrome and highlighted the need for vigilant monitoring and aggressive therapy for this serious complication. Loperamide remains the standard therapy for uncomplicated cases. However, the revised guidelines reflect the need for recognition of the early warning signs of complicated cases of diarrhea and the need for early and aggressive management, including the addition of antibiotics. Management of radiation-induced diarrhea is similar but may not require hospitalization, and chronic low- to intermediate-grade symptoms can be managed with continued loperamide. Conclusion With vigilant monitoring and aggressive therapy for cancer treatment-induced diarrhea, particularly in patients with early warning signs of severe complications, morbidity and mortality may be reduced.
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
Novak, Anne J. , Grote, Deanna M., Stenson, Mary, Ziesmer, Steven C., Harder, Brandon , Ristow, Kay M., Bram, Richard J. , Jelinek, Diane F., Gross, Jane A. , Ansell, Stephen M. , Witzig, Thomas E. , Habermann, Thomas M.

Blood | July 14, 2004 | Volume: 104 | Issue: 8 | Pages: 2247-2253

10.1182/blood-2004-02-0762 | PMID 15251985 Get It

Abstract BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.
Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130
Martenson, James A., Willett, Christopher G. , Sargent, Daniel J. , Mailliard, James A., Donohue, John H., Gunderson, Leonard L., Thomas, Charles R., Fisher, Barbara, Benson, Al B. , Myerson, Robert J., Goldberg, Richard M. , Sargent, Daniel J

Journal of Clinical Oncology | July 13, 2004 | Volume: 22 | Issue: 16 | Pages: 3277-3283

10.1200/jco.2004.01.029 | PMID 15249584 Get It

Purpose Some patients with colon cancer have a high risk of local recurrence postoperatively. This trial was undertaken to determine whether radiation therapy added to an adjuvant chemotherapy regimen improves outcome in high-risk patients. Patients and Methods Patients with resected colon cancer with tumor adherence or invasion of surrounding structures, or with T3N1 or T3N2 tumors of the ascending or descending colon were randomly assigned to receive fluorouracil and levamisole therapy with or without radiation therapy. Patients who received chemotherapy and radiation therapy (chemoRT) received 45 to 50.4 Gy in 25 to 28 fractions beginning 28 days after starting chemotherapy. Patient enrollment was terminated because of slow accrual after 222 patients enrolled (original goal was 700 patients); 187 patients were assessable. Results Overall 5-year survival was 62% for chemotherapy patients and 58% for chemoRT patients (P > .50); 5-year disease-free survival was 51% for both groups (P > .50). Toxicity (≥ grade 3) occurred in 42% of chemotherapy patients and 54% of chemoRT patients (P = .04). Leukopenia (≥ grade 3) occurred in 10% of chemotherapy patients and 22% of chemoRT patients (P = .02). No significant difference in nonhematologic toxicity (≥ grade 3) was observed between chemoRT and chemotherapy patients (35% v 44%; P = .26). Conclusion Patients who received chemotherapy or chemoRT had similar overall survival and disease-free survival. Toxicity was higher among chemoRT patients. These results must be interpreted with caution because of the high number of ineligible patients and the limited power of the study to detect potentially meaningful differences.
Association of Atrial Fibrillation and Obstructive Sleep Apnea
Gami, Apoor S., Pressman, Gregg S. , Caples, Sean M., Kanagala, Ravi, Gard, Joseph J., Davison, Diane E., Malouf, Joseph F., Ammash, Naser M., Friedman, Paul A. , Somers, Virend K.

Circulation | July 13, 2004 | Volume: 110 | Issue: 4 | Pages: 364-367

10.1161/01.cir.0000136587.68725.8e | PMID 15249509 Get It

Background— Obstructive sleep apnea (OSA) is associated with recurrent atrial fibrillation (AF) after electrocardioversion. OSA is highly prevalent in patients who are male, obese, and/or hypertensive, but its prevalence in patients with AF is unknown. Methods and Results— We prospectively studied consecutive patients undergoing electrocardioversion for AF (n=151) and consecutive patients without past or current AF referred to a general cardiology practice (n=312). OSA was diagnosed with the Berlin questionnaire, which is validated to identify patients with OSA. We also assessed its accuracy compared with polysomnography in a sample of the study population. Groups were compared with the 2-tailed t , Wilcoxon, and χ 2 tests. Logistic regression modeled the association of AF and OSA after adjustment for relevant covariates. Patients in each group had similar age, gender, body mass index, and rates of diabetes, hypertension, and congestive heart failure. The questionnaire performed with 0.86 sensitivity, 0.89 specificity, and 0.97 positive predictive value in our sample. The proportion of patients with OSA was significantly higher in the AF group than in the general cardiology group (49% versus 32%, P =0.0004). The adjusted odds ratio for the association between AF and OSA was 2.19 (95% CI 1.40 to 3.42, P =0.0006). Conclusions— The novel finding of this study is that a strong association exists between OSA and AF, such that OSA is strikingly more prevalent in patients with AF than in high-risk patients with multiple other cardiovascular diseases. The coinciding epidemics of obesity and AF underscore the clinical importance of these results.